+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of 12-month nasal continuous positive airway pressure therapy for obstructive sleep apnea on progression of chronic kidney disease



Effect of 12-month nasal continuous positive airway pressure therapy for obstructive sleep apnea on progression of chronic kidney disease



Medicine 98(8): E14545



Obstructive sleep apnea (OSA) is common among patients with chronic kidney disease (CKD). CKD may increase the risk of OSA, and OSA may increase the risk of renal injury. Nasal continuous positive airway pressure (nCPAP) is the standard treatment for OSA. However, the effect of nCPAP on the progression of CKD is unclear. A total of 395 patients with stage 3/4 CKD were initially examined, and 269 patients (148 non-OSA cases; 79 mild OSA cases; 42 moderate/severe OSA cases) were analyzed after implementation of the exclusion criteria. The severity of OSA was determined by polysomnography (PSG). Fifty-two OSA patients (32 mild OSA cases; 20 moderate/severe OSA cases) received nCPAP treatment for 12 months. Variables associated with OSA severity and estimated glomerular filtration rate (eGFR) were evaluated before and after the 12-month nCPAP treatment. Among all 269 CKD patients, body mass index (BMI), and eGFR had significant associations with OSA severity. Age, BMI, apnea-hypopnea index (AHI), mean SaO2%, and SaO2 <90% monitoring time had independent associations with lower eGFR. The 12-month nCPAP treatment significantly reduced the rate of eGFR decline. Univariate and multivariate analysis indicated that age, BMI, AHI, mean SaO2%, and SaO2 <90% monitoring time were independently associated with reduced eGFR. Furthermore, nCPAP treatment significantly improved eGFR, AHI, mean SaO2, and SaO2 <90% monitoring time in patients with mild OSA, and improved systolic/diastolic blood pressure, urinary protein level, eGFR, AHI, mean SaO2, and SaO2 <90% monitoring time for patients with moderate/severe OSA. This study of patients with CKD and OSA indicated that nCPAP therapy significantly ameliorated CKD progression, especially in those with moderate/severe OSA.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066538652

Download citation: RISBibTeXText

PMID: 30813163


Related references

Magnetic resonance imaging of the upper airway in obstructive sleep apnea before and after chronic nasal continuous positive airway pressure therapy. American Review of Respiratory Disease 144(4): 939-944, 1991

Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure. American Review of Respiratory Disease 148(1): 173-178, 1993

Effect of nasal continuous positive airway pressure on obstructive sleep apnea Long-term therapy and its patient compliance. Togawa, K , Katayama, S , Hishikawa, Y , Ohto, Y , Horie, T Sleep apnea and rhonchopathy : 28-32, 1993

Daytime sleepiness and nasal continuous positive airway pressure therapy in obstructive sleep apnea syndrome patients: Effects of chronic treatment and 1-night therapy withdrawal. Sleep 18(3): 195-201, 1995

Acute effect of nasal continuous positive airway pressure therapy on the systemic immunity of patients with obstructive sleep apnea syndrome. Sleep 24(5): 545-553, 2001

Effects of therapy by nasal continuous positive airway pressure cpap in four patients with a sleep apnea syndrome sas six month follow up improvements of apnea index sleep quality and neuropsychological function. Levi-Valensi, P And B Duron (Ed ) Colloque Inserm (Institute National De La Sante Et De La Recherche Medicale), Vol 167 Les Evenements Respiratoires Du Sommeil; (Inserm (National Institute Of Health And Medical Research) Colloquium, Vol 167 Sleep Disorders And Respiration); Meeting, Amiens, France, November 19-20, 1987 Xvi+307p Les Editions Inserm: Paris, France; John Libbey And Co Ltd: London, England, Uk Illus Paper 231-234, 1988

Nasal continuous positive airway pressure therapy in obstructive sleep apnea syndrome. Zhonghua Jie he He Hu Xi Za Zhi 14(4): 225-7 256, 1991

Histology of nasal mucosa in untreated obstructive sleep apnea syndrome and during nasal continuous positive airway pressure therapy. FASEB Journal 16(4): A359-A360, 2002

Effect of adherence on daytime sleepiness, fatigue, depression and sleep quality in the obstructive sleep apnea/hypopnea syndrome patients undertaking nasal continuous positive airway pressure therapy. Patient Preference and Adherence 11: 769-779, 2017

Nasal nitric oxide improved by continuous positive airway pressure therapy for upper airway inflammation in obstructive sleep apnea. Sleep and Breathing 21(2): 405-410, 2017

Increased propensity for central apnea in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure. American Journal of Respiratory and Critical Care Medicine 181(2): 189-193, 2010

Bed partners' assessment of nasal continuous positive airway pressure therapy in obstructive sleep apnea. Chest 111(5): 1261-1265, 1997

The effect of nasal continuous positive airway pressure on endothelial function in obstructive sleep apnea-hypopnea syndrome with coronary heart disease. Zhonghua Nei Ke Za Zhi 45(3): 188-191, 2006

Effect of Nasal Continuous Positive Airway Pressure Therapy on the Functional Respiratory Parameters and Cardiopulmonary Exercise Test in Obstructive Sleep Apnea Syndrome. Turkish Thoracic Journal 17(1): 1-6, 2016

Effect of nasal continuous positive airway pressure during sleep on 24-hour blood pressure in obstructive sleep apnea. Sleep 16(6): 539-544, 1993